PMID- 24247547
OWN - NLM
STAT- MEDLINE
DCOM- 20140818
LR  - 20220316
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 44
IP  - 1
DP  - 2014 Jan
TI  - Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and 
      treatment patterns in clinical practice from a global medical chart review.
PG  - 5-16
LID - 10.3892/ijo.2013.2181 [doi]
AB  - The aim of this study was to assess the treatment patterns and safety of 
      sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, 
      Europe and Asia. Medical records were abstracted at 18 community oncology clinics 
      in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 
      patients >/= 18 years who had histologically/cytologically confirmed diagnosis of 
      advanced RCC and received sunitinib (n=631), sorafenib (n=207) or bevacizumab 
      (n=45) as first-line treatment. No prior treatment was permitted. Data were 
      collected on all adverse events (AEs) and treatment modifications, including 
      discontinuation, interruption and dose reduction. Treatment duration was 
      estimated using Kaplan-Meier analysis. Demographics were similar across treatment 
      groups and regions. Median treatment duration ranged from 6.1 to 10.7 months, 5.1 
      to 8.5 months and 7.5 to 9.8 months for sunitinib, sorafenib and bevacizumab 
      patients, respectively. Grade 3/4 AEs were experienced by 26.0, 28.0 and 15.6% of 
      sunitinib, sorafenib and bevacizumab patients, respectively. Treatment 
      discontinuations occurred in 62.4 (Asia) to 63.1% (US) sunitinib, 68.8 (Asia) to 
      90.0% (Europe) sorafenib, and 66.7 (Asia) to 81.8% (US) bevacizumab patients. 
      Globally, treatment modifications due to AEs occurred in 55.1, 54.2 and 50.0% 
      sunitinib, sorafenib and bevacizumab patients, respectively. This study in a 
      large, global cohort of advanced RCC patients found that angiogenesis inhibitors 
      are associated with high rates of AEs and treatment modifications. Findings 
      suggest an unmet need for more tolerable agents for RCC treatment.
FAU - Oh, William K
AU  - Oh WK
AD  - Dana-Farber Cancer Institute, Boston, MA, USA.
FAU - McDermott, David
AU  - McDermott D
FAU - Porta, Camillo
AU  - Porta C
FAU - Levy, Antonin
AU  - Levy A
FAU - Elaidi, Reza
AU  - Elaidi R
FAU - Scotte, Florian
AU  - Scotte F
FAU - Hawkins, Robert
AU  - Hawkins R
FAU - Castellano, Daniel
AU  - Castellano D
FAU - Bellmunt, Joaquim
AU  - Bellmunt J
FAU - Rha, Sun Young
AU  - Rha SY
FAU - Sun, Jong-Mu
AU  - Sun JM
FAU - Nathan, Paul
AU  - Nathan P
FAU - Feinberg, Bruce A
AU  - Feinberg BA
FAU - Scott, Jeffrey
AU  - Scott J
FAU - McDermott, Ray
AU  - McDermott R
FAU - Ahn, Jin-Hee
AU  - Ahn JH
FAU - Wagstaff, John
AU  - Wagstaff J
FAU - Chang, Yen-Hwa
AU  - Chang YH
FAU - Ou, Yen-Chuan
AU  - Ou YC
FAU - Donnellan, Paul
AU  - Donnellan P
FAU - Huang, Chao-Yuan
AU  - Huang CY
FAU - McCaffrey, John
AU  - McCaffrey J
FAU - Chiang, Po-Hui
AU  - Chiang PH
FAU - Chuang, Cheng-Keng
AU  - Chuang CK
FAU - Korves, Caroline
AU  - Korves C
FAU - Neary, Maureen P
AU  - Neary MP
FAU - Diaz, Jose R
AU  - Diaz JR
FAU - Mehmud, Faisal
AU  - Mehmud F
FAU - Duh, Mei Sheng
AU  - Duh MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131115
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Indoles)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyrroles)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/administration & dosage/adverse effects
MH  - Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects
MH  - Asia
MH  - Bevacizumab
MH  - Carcinoma, Renal Cell/*drug therapy/epidemiology/pathology
MH  - Drug-Related Side Effects and Adverse Reactions/pathology
MH  - Europe
MH  - Female
MH  - Humans
MH  - Indoles/*administration & dosage/adverse effects
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & derivatives
MH  - Phenylurea Compounds/*administration & dosage/adverse effects
MH  - Pyrroles/*administration & dosage/adverse effects
MH  - Sorafenib
MH  - Sunitinib
MH  - Treatment Outcome
MH  - United States
PMC - PMC3867384
EDAT- 2013/11/20 06:00
MHDA- 2014/08/19 06:00
PMCR- 2013/11/15
CRDT- 2013/11/20 06:00
PHST- 2013/08/12 00:00 [received]
PHST- 2013/10/09 00:00 [accepted]
PHST- 2013/11/20 06:00 [entrez]
PHST- 2013/11/20 06:00 [pubmed]
PHST- 2014/08/19 06:00 [medline]
PHST- 2013/11/15 00:00 [pmc-release]
AID - ijo-44-01-0005 [pii]
AID - 10.3892/ijo.2013.2181 [doi]
PST - ppublish
SO  - Int J Oncol. 2014 Jan;44(1):5-16. doi: 10.3892/ijo.2013.2181. Epub 2013 Nov 15.